Archive · 13 Jun 2025
Bharat Biotech and GSK Partner on Shigella Vaccine Development
Imagine a nasty tummy bug called Shigella that mostly makes little kids sick.
Scientists are working on a vaccine to stop it.
Bharat Biotech and GSK are teaming up to develop a new vaccine, altSonflex1-2-3.
It has shown good results in early tests and is made using a special method called GMMA.
Bharat Biotech will lead the next stage of testing and making the vaccine.
The goal is to create a vaccine that's easy to get and can protect kids all over the world from this nasty bug.
Bharat Biotech partners with GSK to develop Shigella vaccine candidate altSonflex1-2-3.
The vaccine targets Shigellosis, a severe bacterial diarrhoea affecting children.
The vaccine has shown promising results in early-stage clinical trials.
Bharat Biotech will lead Phase 3 trials, regulatory advancement, and manufacturing.
The collaboration aims to create an affordable, globally accessible vaccine.
- Who
- Bharat Biotech and GSK are collaborating.
- What
- Collaboration to advance Shigella vaccine development.
- When
- Announced recently with interim results from 2024.
- Where
- Hyderabad, India, and clinical trials in Europe and Africa.
- Why
- To develop and provide access to a Shigella vaccine for children, combating a serious bacterial infection and antimicrobial resistance.
Benefits
Challenges
Public Health Impact
Benefits
Preventing severe diarrhea.
Challenges
Reducing child mortality and morbidity.
Antimicrobial Resistance
Benefits
Potential to combat antimicrobial resistance.
Challenges
Decreasing antibiotic use.
- Vaccine Name
- altSonflex1-2-3
- Target Disease
- Shigellosis (bacterial diarrhoea)
- Companies Involved
- Bharat Biotech, GSK
- Vaccine Technology
- GMMA (Generalized Modules for Membrane Antigens)
- Trial Phase
- Phase 3 planned
- Primary Target
- Children under five